The Role of Neurokinin-1 Receptor in the Microenvironment of Inflammation and Cancer

Overview

Journal ScientificWorldJournal

Publisher Wiley

Specialty Biology

Date 2012 May 1

PMID 22545017

Citations 38

Authors

Marisa Rosso

Miguel Munoz

Michael Berger

Affiliations

Soon will be listed here.

Abstract

The recent years have witnessed an exponential increase in cancer research, leading to a considerable investment in the field. However, with few exceptions, this effort has not yet translated into a better overall prognosis for patients with cancer, and the search for new drug targets continues. After binding to the specific neurokinin-1 (NK-1) receptor, the peptide substance P (SP), which is widely distributed in both the central and peripheral nervous systems, triggers a wide variety of functions. Antagonists against the NK-1 receptor are safe clinical drugs that are known to have anti-inflammatory, analgesic, anxiolytic, antidepressant, and antiemetic effects. Recently, it has become apparent that SP can induce tumor cell proliferation, angiogenesis, and migration via the NK-1 receptor, and that the SP/NK-1 receptor complex is an integral part of the microenvironment of inflammation and cancer. Therefore, the use of NK-1 receptor antagonists as a novel and promising approach for treating patients with cancer is currently under intense investigation. In this paper, we evaluate the recent scientific developments regarding this receptor system, its role in the microenvironment of inflammation and cancer, and its potentials and pitfalls for the usage as part of modern anticancer strategies.

Citing Articles

The use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer.

Martin-Garcia D, Tellez T, Redondo M, Garcia-Aranda M Curr Med Chem. 2023; 31(39):6487-6509.

PMID: 37861026 DOI: 10.2174/0109298673261625230924114406.

Expression of substance P, neurokinin 1 receptor, Ki-67 and pyruvate kinase M2 in hormone receptor negative breast cancer and evaluation of impact on overall survival.

Al-Keilani M, Bdeir R, Elstaty R, Alqudah M BMC Cancer. 2023; 23(1):158.

PMID: 36797689 PMC: 9936699. DOI: 10.1186/s12885-023-10633-8.

Preparation and Characterization of Aprepitant Solid Dispersion with HPMCAS-LF.

Liu J, Li Y, Ao W, Xiao Y, Bai M, Li S ACS Omega. 2022; 7(44):39907-39912.

PMID: 36385804 PMC: 9647728. DOI: 10.1021/acsomega.2c04021.

The Effect of Blocking Neurokinin-1 Receptor by Aprepitant on the Inflammatory and Apoptosis Pathways in Human Ovarian Cancer Cells.

Alalikhan A, Ghahremanloo A, Javid H, Ebrahimi S, Hashemy S Cell Biochem Biophys. 2022; 80(4):819-827.

PMID: 36197642 DOI: 10.1007/s12013-022-01100-5.

Upregulated expression of substance P and NK1R in blood monocytes and B cells of patients with allergic rhinitis and asthma.

Han P, Chen L, Chen D, Yang R, Wang W, Liu J Clin Exp Immunol. 2022; 210(1):39-52.

PMID: 36001730 PMC: 9585549. DOI: 10.1093/cei/uxac074.

References

MacArthur M, Hold G, El-Omar E . Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol. 2004; 286(4):G515-20. DOI: 10.1152/ajpgi.00475.2003. View

Navari R . Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs. 2007; 16(12):1977-85. DOI: 10.1517/13543784.16.12.1977. View

Castro T, Cohen M, Rameshwar P . The expression of neurokinin-1 and preprotachykinin-1 in breast cancer cells depends on the relative degree of invasive and metastatic potential. Clin Exp Metastasis. 2006; 22(8):621-8. DOI: 10.1007/s10585-006-9001-6. View

Rupniak N, Carlson E, Boyce S, Webb J, Hill R . Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733,060 in gerbils. Pain. 1996; 67(1):189-195. DOI: 10.1016/0304-3959(96)03109-0. View

Luttrell L, Ferguson S, Daaka Y, Miller W, Maudsley S, Della Rocca G . Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science. 1999; 283(5402):655-61. DOI: 10.1126/science.283.5402.655. View

Folkman J . Fighting cancer by attacking its blood supply. Sci Am. 1996; 275(3):150-4. DOI: 10.1038/scientificamerican0996-150. View

Palma C . Tachykinins and their receptors in human malignancies. Curr Drug Targets. 2006; 7(8):1043-52. DOI: 10.2174/138945006778019282. View

Castagliuolo I, Valenick L, Liu J, Pothoulakis C . Epidermal growth factor receptor transactivation mediates substance P-induced mitogenic responses in U-373 MG cells. J Biol Chem. 2000; 275(34):26545-50. DOI: 10.1074/jbc.M003990200. View

Koon H, Zhao D, Na X, Moyer M, Pothoulakis C . Metalloproteinases and transforming growth factor-alpha mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes. J Biol Chem. 2004; 279(44):45519-27. DOI: 10.1074/jbc.M408523200. View

10.

van Ginkel F, Pascual D . Recognition of neurokinin 1 receptor (NK1-R): an antibody to a peptide sequence from the third extracellular region binds to brain NK1-R. J Neuroimmunol. 1996; 67(1):49-58. DOI: 10.1016/s0165-5728(96)00033-1. View

11.

Lowes V, Ip N, Wong Y . Integration of signals from receptor tyrosine kinases and g protein-coupled receptors. Neurosignals. 2002; 11(1):5-19. DOI: 10.1159/000057317. View

12.

Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S . Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010; 70(6):2235-44. DOI: 10.1158/0008-5472.CAN-09-2335. View

13.

Ziche M, Morbidelli L, Pacini M, Geppetti P, Alessandri G, Maggi C . Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res. 1990; 40(2):264-78. DOI: 10.1016/0026-2862(90)90024-l. View

14.

Ho A, Fusenig N . Cancer stem cells: a promising concept and therapeutic challenge. Int J Cancer. 2011; 129(10):2309. DOI: 10.1002/ijc.26409. View

15.

Entschladen F, Lang K, Drell T, Joseph J, Zaenker K . Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunol Immunother. 2002; 51(9):467-82. PMC: 11033027. DOI: 10.1007/s00262-002-0300-8. View

16.

Hilakivi-Clarke L, Rowland J, Clarke R, Lippman M . Psychosocial factors in the development and progression of breast cancer. Breast Cancer Res Treat. 1994; 29(2):141-60. DOI: 10.1007/BF00665676. View

17.

Snider R, CONSTANTINE J, Lowe 3rd J, Longo K, Lebel W, Woody H . A potent nonpeptide antagonist of the substance P (NK1) receptor. Science. 1991; 251(4992):435-7. DOI: 10.1126/science.1703323. View

18.

Wiedermann C, Auer B, Sitte B, Reinisch N, Schratzberger P, Kahler C . Induction of endothelial cell differentiation into capillary-like structures by substance P. Eur J Pharmacol. 1996; 298(3):335-8. DOI: 10.1016/0014-2999(95)00818-7. View

19.

Koyama S, Sato E, Nomura H, Kubo K, NAGAI S, Izumi T . Acetylcholine and substance P stimulate bronchial epithelial cells to release eosinophil chemotactic activity. J Appl Physiol (1985). 1998; 84(5):1528-34. DOI: 10.1152/jappl.1998.84.5.1528. View

20.

Almeida T, Rojo J, Nieto P, Pinto F, Hernandez M, Martin J . Tachykinins and tachykinin receptors: structure and activity relationships. Curr Med Chem. 2004; 11(15):2045-81. DOI: 10.2174/0929867043364748. View